Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States
MADISON, Wis.--(BUSINESS WIRE)--Feb 28, 2024--
Source: eagletribune.com
Stay updated with breaking news from Recurrence Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MADISON, Wis.--(BUSINESS WIRE)--Feb 28, 2024--
Exact Sciences Corporation (NASDAQ: EXAS) shares are trading higher Wednesday, and the stock has gained over 8% in the past month. Here's a look at the latest Exact Sciences news: What To Know:
For postmenopausal women aged 50 to 69 years with stage 1 hormone receptor-positive breast cancer, the risk for recurrence is very low for those who do not undergo radiotherapy after BCS.
Unveiling the Strengths and Challenges: A Deep Dive into Exact Sciences Corp (EXAS) SWOT Analysis